{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:56:22Z","timestamp":1789692982328,"version":"4.0.1"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cellimm.2022.104641","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:07:54Z","timestamp":1668391674000},"page":"104641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies"],"prefix":"10.1016","volume":"382","author":[{"given":"Jyoti","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite Melero","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-5905","authenticated-orcid":false,"given":"Moanaro","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2022.104641_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0010","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.cellimm.2022.104641_b0025","first-page":"15","article-title":"Immunogenicity of biological therapeutics: a hierarchy of concerns","volume":"112","author":"Rosenberg","year":"2003","journal-title":"Dev. Biol. (Basel)"},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0030","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrd3974","article-title":"Challenges and approaches for the development of safer immunomodulatory biologics","volume":"12","author":"Sathish","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"49","key":"10.1016\/j.cellimm.2022.104641_b0035","first-page":"560","article-title":"The immunogenicity of therapeutic proteins","volume":"9","author":"Schellekens","year":"2010","journal-title":"Discov. Med."},{"issue":"11","key":"10.1016\/j.cellimm.2022.104641_b0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","article-title":"Immunogenicity of protein therapeutics","volume":"28","author":"De Groot","year":"2007","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0050","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0060","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","article-title":"Burden of illness: direct and indirect costs among persons with hemophilia A in the United States","volume":"18","author":"Zhou","year":"2015","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0075","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the international immune tolerance study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2516.2006.01212.x","article-title":"Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature","volume":"12","author":"Biss","year":"2006","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease","volume":"137","author":"Garman","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0100","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.4049\/jimmunol.1303326","article-title":"Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa","volume":"193","author":"Joly","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2022.104641_b0105","first-page":"11","article-title":"Immune modulation therapy in a CRIM-positive and igg antibody-positive infant with pompe disease treated with alglucosidase alfa: a case report","volume":"2","author":"Markic","year":"2012","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1055\/s-0037-1616733","article-title":"Blockade of CD40\/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance","volume":"86","author":"Reipert","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2022.104641_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clim.2017.01.014","article-title":"Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice","volume":"178","author":"Sato","year":"2017","journal-title":"Clin Immunol"},{"issue":"01","key":"10.1016\/j.cellimm.2022.104641_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1160\/TH16-05-0404","article-title":"Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin","volume":"117","author":"Biswas","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0130","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jth.14740","article-title":"Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors","volume":"18","author":"Doshi","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.cellimm.2022.104641_b0135","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","article-title":"High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors","volume":"128","author":"Batsuli","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2022.104641_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","article-title":"In vivo induction of regulatory T cells for immune tolerance in hemophilia","volume":"301","author":"Wang","year":"2016","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.0105-2896.2005.00280.x","article-title":"Oral tolerance","volume":"206","author":"Faria","year":"2005","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4049\/jimmunol.140.2.440","article-title":"Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments","volume":"140","author":"Higgins","year":"1988","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0008-8749(88)90305-X","article-title":"Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein","volume":"112","author":"Bitar","year":"1988","journal-title":"Cell. Immunol."},{"issue":"19","key":"10.1016\/j.cellimm.2022.104641_b0160","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1073\/pnas.83.19.7443","article-title":"Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen","volume":"83","author":"Nagler-Anderson","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/jaut.2000.0471","article-title":"Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse","volume":"16","author":"Maron","year":"2001","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0170","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1572-0241.2000.01935.x","article-title":"Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes","volume":"95","author":"Ilan","year":"2000","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0175","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/eji.200838418","article-title":"Neonatal exposure to staphylococcal superantigen improves induction of oral tolerance in a mouse model of airway allergy","volume":"39","author":"L\u00f6nnqvist","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0180","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","article-title":"Oral tolerance","volume":"241","author":"Weiner","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2022.104641_b0185","unstructured":"Besredka, A., De l\u2019anaphylaxie. Sixi me memoire de l\u2019anaphykaxie lactique. Ann. Inst. Pasteur. 33 (1909) 166\u2013174."},{"key":"10.1016\/j.cellimm.2022.104641_b0190","doi-asserted-by":"crossref","unstructured":"H.G. Wells, T.B. Osborne, The biological reactions of the vegetable proteins I. Anaphylaxis. 1911, J. Infect. Dis. 8 (1) (1911) 66\u2013124.","DOI":"10.1093\/infdis\/8.1.66"},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0195","first-page":"581","article-title":"Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats","volume":"64","author":"Thompson","year":"1986","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","article-title":"Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective","volume":"139","author":"Vickery","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0205","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jaip.2017.09.016","article-title":"Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial","volume":"6","author":"Bird","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0210","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1467-7652.2011.00613.x","article-title":"Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression","volume":"9","author":"Suzuki","year":"2011","journal-title":"Plant Biotechnol. J."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0215","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/cmi.2011.13","article-title":"Construction of a Der p2-transgenic plant for the alleviation of airway inflammation","volume":"8","author":"Lee","year":"2011","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/pbi.12007","article-title":"Oral immunotherapy with transgenic rice seed containing destructed Japanese cedar pollen allergens, Cry j 1 and Cry j 2, against Japanese cedar pollinosis","volume":"11","author":"Wakasa","year":"2013","journal-title":"Plant Biotechnol. J."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0225","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10875-015-0160-6","article-title":"Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial","volume":"35","author":"Lalazar","year":"2015","journal-title":"J. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0230","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/pbi.12413","article-title":"Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice","volume":"13","author":"Su","year":"2015","journal-title":"Plant Biotechnol. J."},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0235","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/pbi.12223","article-title":"Suppression of collagen-induced arthritis by oral administration of transgenic rice seeds expressing altered peptide ligands of type II collagen","volume":"12","author":"Iizuka","year":"2014","journal-title":"Plant Biotechnol. J."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0240","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/pbi.12479","article-title":"Feeding transgenic plants that express a tolerogenic fusion protein effectively protects against arthritis","volume":"14","author":"Hansson","year":"2016","journal-title":"Plant Biotechnol. J."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0245","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00125-018-4593-3","article-title":"Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice","volume":"61","author":"Chen","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cellimm.2022.104641_b0250","doi-asserted-by":"crossref","first-page":"42372","DOI":"10.1038\/srep42372","article-title":"Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: evaluating oral tolerance mechanisms and disease prevention in NOD mice","volume":"7","author":"Posgai","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.cellimm.2022.104641_b0255","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood-2013-10-528737","article-title":"Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells","volume":"124","author":"Sherman","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0260","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/pbi.12859","article-title":"Expression and assembly of largest foreign protein in chloroplasts: oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in haemophilia A mice","volume":"16","author":"Kwon","year":"2018","journal-title":"Plant Biotechnol. J."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0265","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ymthe.2016.11.009","article-title":"Oral tolerance induction in hemophilia B dogs fed with transplastomic lettuce","volume":"25","author":"Herzog","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2022.104641_b0270","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biomaterials.2015.08.004","article-title":"Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B","volume":"70","author":"Su","year":"2015","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.anai.2018.06.005","article-title":"FDA-approved peanut allergy treatment: The first wave is about to crest","volume":"121","author":"Tilles","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.cellimm.2022.104641_b0280","doi-asserted-by":"crossref","unstructured":"P.G.o.C. Investigators, et al., AR101 oral immunotherapy for peanut allergy, N. Engl. J. Med. 379 (21) (2018) 1991\u20132001.","DOI":"10.1056\/NEJMoa1812856"},{"issue":"5176","key":"10.1016\/j.cellimm.2022.104641_b0285","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7520605","article-title":"Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis","volume":"265","author":"Chen","year":"1994","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.cellimm.2022.104641_b0290","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.91.14.6688","article-title":"Induction of anergy or active suppression following oral tolerance is determined by antigen dosage","volume":"91","author":"Friedman","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.cellimm.2022.104641_b0295","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.4049\/jimmunol.147.7.2155","article-title":"Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy","volume":"147","author":"Whitacre","year":"1991","journal-title":"J. Immunol."},{"issue":"6536","key":"10.1016\/j.cellimm.2022.104641_b0300","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/376177a0","article-title":"Peripheral deletion of antigen-reactive T cells in oral tolerance","volume":"376","author":"Chen","year":"1995","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0305","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.4049\/jimmunol.162.9.5317","article-title":"Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance","volume":"162","author":"Itoh","year":"1999","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0310","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20020190","article-title":"Interleukin 2 signaling is required for CD4(+) regulatory T cell function","volume":"196","author":"Furtado","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2022.104641_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.704578","article-title":"Conversion of anergic T cells into Foxp3(-) IL-10(+) regulatory T cells by a second antigen stimulus in vivo","volume":"12","author":"Thomann","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0320","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/eji.201243154","article-title":"On the road to tolerance\u2013generation and migration of gut regulatory T cells","volume":"43","author":"Pabst","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.cellimm.2022.104641_b0325","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1172\/JCI24487","article-title":"Oral tolerance in the absence of naturally occurring Tregs","volume":"115","author":"Mucida","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"7385","key":"10.1016\/j.cellimm.2022.104641_b0330","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10772","article-title":"Extrathymically generated regulatory T cells control mucosal TH2 inflammation","volume":"482","author":"Josefowicz","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0335","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20070590","article-title":"A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism","volume":"204","author":"Coombes","year":"2007","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0340","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.immuni.2011.01.016","article-title":"Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria","volume":"34","author":"Hadis","year":"2011","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0345","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1084\/jem.20070602","article-title":"Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid","volume":"204","author":"Sun","year":"2007","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0350","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.4049\/jimmunol.1101398","article-title":"Inducible CD4+LAP+Foxp3- regulatory T cells suppress allergic inflammation","volume":"187","author":"Duan","year":"2011","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0355","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nm1408","article-title":"Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells","volume":"12","author":"Ochi","year":"2006","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0360","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1053\/j.gastro.2012.07.019","article-title":"An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice","volume":"143","author":"Forster","year":"2012","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0365","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/eji.200425274","article-title":"Interleukin-2 is essential for CD4+CD25+ regulatory T cell function","volume":"34","author":"de la Rosa","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0370","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0375","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0380","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nm924","article-title":"TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes","volume":"9","author":"Belghith","year":"2003","journal-title":"Nat. Med."},{"issue":"5955","key":"10.1016\/j.cellimm.2022.104641_b0385","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.1172702","article-title":"CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner","volume":"326","author":"Chaudhry","year":"2009","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0390","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.immuni.2011.01.020","article-title":"Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner","volume":"34","author":"Huber","year":"2011","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0395","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"issue":"5899","key":"10.1016\/j.cellimm.2022.104641_b0400","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0405","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0410","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.172.4.1091","article-title":"In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B","volume":"172","author":"Rellahan","year":"1990","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0415","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.4049\/jimmunol.147.12.4118","article-title":"Clonal anergy blocks the response to IL-4, as well as the production of IL-2, in dual-producing T helper cell clones","volume":"147","author":"Mueller","year":"1991","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0420","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4049\/jimmunol.149.3.901","article-title":"Induction of competence to respond to IL-4 by CD4+ T helper type 1 cells requires costimulation","volume":"149","author":"Chiodetti","year":"1992","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0425","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jaci.2014.11.010","article-title":"Suppression of the immunologic response to peanut during immunotherapy is often transient","volume":"135","author":"Gorelik","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0430","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0435","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4168\/aair.2017.9.1.35","article-title":"Oral food desensitization in children with IgE-mediated cow's milk allergy: immunological changes underlying desensitization","volume":"9","author":"Perez\u00e1bad","year":"2017","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0440","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1520180113","article-title":"Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets","volume":"113","author":"Ryan","year":"2016","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0445","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","article-title":"Human T regulatory cells can use the perforin pathway to cause autologous target cell death","volume":"21","author":"Grossman","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0450","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.174.4.1783","article-title":"Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism","volume":"174","author":"Gondek","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0455","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.4049\/jimmunol.168.5.2188","article-title":"Administration of an antigen at a high dose generates regulatory CD4+ T cells expressing CD95 ligand and secreting IL-4 in the liver","volume":"168","author":"Watanabe","year":"2002","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0460","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0092-8674(94)90332-8","article-title":"Lymphocyte responses and cytokines","volume":"76","author":"Paul","year":"1994","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0465","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/90604","article-title":"The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells","volume":"2","author":"Weiner","year":"2001","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0470","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(01)00147-9","article-title":"TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu","volume":"14","author":"Chen","year":"2001","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0475","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0480","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1189\/jlb.0503228","article-title":"The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets","volume":"74","author":"Horwitz","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0485","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.cdd.4401699","article-title":"Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion","volume":"13","author":"Kleinclauss","year":"2006","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2009.02.024","article-title":"It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response","volume":"9","author":"Peron","year":"2009","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0495","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41385-019-0240-7","article-title":"Goblet cell associated antigen passages support the induction and maintenance of oral tolerance","volume":"13","author":"Kulkarni","year":"2020","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0500","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","article-title":"Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo","volume":"194","author":"Hawiger","year":"2001","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0505","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/gut.2009.185108","article-title":"Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory\/T effector cell balance and oral tolerance induction","volume":"59","author":"Matteoli","year":"2010","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.cellimm.2022.104641_b0510","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0515","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1074-7613(04)00108-6","article-title":"Autoimmunity through cytokine-induced dendritic cell activation","volume":"20","author":"Banchereau","year":"2004","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0520","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.20032220","article-title":"In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination","volume":"199","author":"Bonifaz","year":"2004","journal-title":"J. Exp. Med."},{"issue":"5835","key":"10.1016\/j.cellimm.2022.104641_b0525","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1145697","article-title":"Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid","volume":"317","author":"Mucida","year":"2007","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0530","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.4049\/jimmunol.179.6.3724","article-title":"Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells","volume":"179","author":"Kang","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0535","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0540","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.cellimm.2022.104641_b0545","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.cellimm.2022.104641_b0550","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/blood-2011-04-349761","article-title":"Cell-intrinsic role for IFN-alpha-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0555","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.4049\/jimmunol.179.5.2690","article-title":"Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype","volume":"179","author":"Contractor","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2022.104641_b0560","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.3389\/fimmu.2018.02883","article-title":"Intestinal dendritic cells in health and gut inflammation","volume":"9","author":"Stagg","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2022.104641_b0565","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3389\/fimmu.2018.02939","article-title":"Regulatory immune mechanisms in tolerance to food allergy","volume":"9","author":"Satitsuksanoa","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0570","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20052016","article-title":"Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells","volume":"203","author":"Worbs","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2022.104641_b0575","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-2776(08)60240-0","article-title":"Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response","volume":"40","author":"Mestecky","year":"1987","journal-title":"Adv. Immunol."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0580","first-page":"157","article-title":"A morphological study of beta-lactoglobulin absorption by cultured explants of the human duodenal mucosa using immunocytochemical and cytochemical techniques","volume":"16","author":"Wheeler","year":"1993","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0585","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1203\/00006450-198808000-00012","article-title":"Antigen absorption by the jejunal epithelium of children with cow's milk allergy","volume":"24","author":"Heyman","year":"1988","journal-title":"Pediatr. Res."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0590","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/eji.200425882","article-title":"Immunomodulatory dendritic cells in intestinal lamina propria","volume":"35","author":"Chirdo","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"6015","key":"10.1016\/j.cellimm.2022.104641_b0595","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1198469","article-title":"Induction of colonic regulatory T cells by indigenous Clostridium species","volume":"331","author":"Atarashi","year":"2011","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0600","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/1521-4141(200204)32:4<1109::AID-IMMU1109>3.0.CO;2-K","article-title":"Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches","volume":"32","author":"Spahn","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"7754","key":"10.1016\/j.cellimm.2022.104641_b0605","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-019-1125-3","article-title":"Compartmentalized gut lymph node drainage dictates adaptive immune responses","volume":"569","author":"Esterh\u00e1zy","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0610","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/mi.2015.77","article-title":"The lymph nodes draining the small intestine and colon are anatomically separate and immunologically distinct","volume":"9","author":"Houston","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2022.104641_b0615","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1074-7613(00)80571-3","article-title":"Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen","volume":"8","author":"G\u00fctgemann","year":"1998","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.cellimm.2022.104641_b0620","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/j.1600-6143.2004.00551.x","article-title":"Role of the liver in peripheral tolerance: induction through oral antigen feeding","volume":"4","author":"Li","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0625","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.20.2.121","article-title":"Absorption of antigens after oral immunisation and the simultaneous induction of specific systemic tolerance","volume":"20","author":"Swarbrick","year":"1979","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0630","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.immuni.2008.06.017","article-title":"Plasmacytoid dendritic cells mediate oral tolerance","volume":"29","author":"Goubier","year":"2008","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.cellimm.2022.104641_b0635","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2007.522","article-title":"A protocol for expression of foreign genes in chloroplasts","volume":"3","author":"Verma","year":"2008","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0640","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/pbi.13556","article-title":"Green giant-a tiny chloroplast genome with mighty power to produce high-value proteins: history and phylogeny","volume":"19","author":"Daniell","year":"2021","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.cellimm.2022.104641_b0645","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fimmu.2020.00844","article-title":"Role of small intestine and gut microbiome in plant-based oral tolerance for hemophilia","volume":"11","author":"Kumar","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cellimm.2022.104641_b0650","doi-asserted-by":"crossref","first-page":"107413","DOI":"10.1016\/j.biotechadv.2019.06.012","article-title":"Plant cell-made protein antigens for induction of Oral tolerance","volume":"37","author":"Daniell","year":"2019","journal-title":"Biotechnol. Adv."},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0655","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/mt.2016.115","article-title":"Oral delivery of protein drugs bioencapsulated in plant cells","volume":"24","author":"Kwon","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2022.104641_b0660","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biomaterials.2015.11.051","article-title":"Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells","volume":"80","author":"Xiao","year":"2016","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.2009.02321.x","article-title":"Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit","volume":"71","author":"Sun","year":"2010","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0670","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1006\/jmbi.2001.4921","article-title":"Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts","volume":"311","author":"Daniell","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.cellimm.2022.104641_b0675","first-page":"153","article-title":"Cholera toxin - a foe & a friend","volume":"133","author":"Sanchez","year":"2011","journal-title":"Indian J. Med. Res."},{"issue":"7","key":"10.1016\/j.cellimm.2022.104641_b0680","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1046\/j.1365-2222.2000.00849.x","article-title":"Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice","volume":"30","author":"Rask","year":"2000","journal-title":"Clin. Exp. Allergy"},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0685","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1073\/pnas.94.9.4610","article-title":"A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes","volume":"94","author":"Bergerot","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0690","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/1529-0131(199908)42:8<1628::AID-ANR10>3.0.CO;2-T","article-title":"Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine","volume":"42","author":"Tarkowski","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"9824","key":"10.1016\/j.cellimm.2022.104641_b0695","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.cellimm.2022.104641_b0700","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2013-01-478669","article-title":"Progress toward inducing immunologic tolerance to factor VIII","volume":"121","author":"Scott","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0705","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2516.2007.01518.x","article-title":"European study on orthopaedic status of haemophilia patients with inhibitors","volume":"13","author":"Morfini","year":"2007","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0710","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0715","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.2000.02327.x","article-title":"The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)","volume":"111","author":"Hay","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.cellimm.2022.104641_b0720","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani","year":"2001","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0725","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/hae.12077","article-title":"Late immune tolerance induction in haemophilia A patients","volume":"19","author":"Meeks","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.cellimm.2022.104641_b0730","first-page":"136","article-title":"Alternative approaches to oral tolerance induction to factor FVIII","author":"Bertolini","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0735","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0740","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12028","article-title":"Immune tolerance in haemophilia: the long journey to the fork in the road","volume":"159","author":"DiMichele","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.cellimm.2022.104641_b0745","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1073\/pnas.0912181107","article-title":"Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice","volume":"107","author":"Verma","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.cellimm.2022.104641_b0750","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/blood-2014-08-597070","article-title":"Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cellimm.2022.104641_b0755","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/pbi.13608","article-title":"Preclinical development of plant-based oral immune modulatory therapy for haemophilia B","volume":"19","author":"Srinivasan","year":"2021","journal-title":"Plant Biotechnol. J."},{"issue":"23","key":"10.1016\/j.cellimm.2022.104641_b0760","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0765","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/ddu476","article-title":"Peripheral nerve and neuromuscular junction pathology in Pompe disease","volume":"24","author":"Falk","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.cellimm.2022.104641_b0770","doi-asserted-by":"crossref","first-page":"e003637","DOI":"10.1161\/CIRCIMAGING.115.003637","article-title":"Giant heart of classical infantile-onset pompe disease with mirror image dextrocardia","volume":"8","author":"Tripathi","year":"2015","journal-title":"Circ. Cardiovasc. Imaging"},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0775","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.cellimm.2022.104641_b0780","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.cellimm.2022.104641_b0785","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000446154","article-title":"IgE-mediated hypersensitivity and desensitisation with recombinant enzymes in pompe disease and type I and type VI mucopolysaccharidosis","volume":"169","author":"Capanoglu","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.cellimm.2022.104641_b0790","doi-asserted-by":"crossref","unstructured":"Z.B. Kazi, et al., Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight 2 (16) (2017).","DOI":"10.1172\/jci.insight.94328"},{"key":"10.1016\/j.cellimm.2022.104641_b0795","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2022.104641_b0800","article-title":"A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation","volume":"32","author":"Curelaru","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.cellimm.2022.104641_b0805","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2011.01.009","article-title":"Oral administration of recombinant human acid alpha-glucosidase reduces specific antibody formation against enzyme in mouse","volume":"103","author":"Ohashi","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.cellimm.2022.104641_b0810","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2012.03.009","article-title":"Mapping the T helper cell response to acid alpha-glucosidase in Pompe mice","volume":"106","author":"Nayak","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.cellimm.2022.104641_b0815","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","article-title":"Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial","volume":"4","author":"J, O.B.H.","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"10.1016\/j.cellimm.2022.104641_b0820","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jaip.2020.12.029","article-title":"Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study","volume":"9","author":"Vickery","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874922001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874922001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T23:12:11Z","timestamp":1757805131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874922001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":164,"alternative-id":["S0008874922001666"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2022.104641","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2022.104641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104641"}}